phrykt

Kailera Therapeutics, Inc. (KLRA): who owns it and who trades it

As of Nov 16, 2026, KLRA insiders reported 3 purchases worth $167M in the last 12 months. The largest buyer was BCPE Perseus Investor, LP (10% owner), with $134M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kailera Therapeutics

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KLRA

100 funds and institutions reported KLRA shares worth $2.6B at the end of Q2 2026, about 90% of the company. The largest holder is Bain Capital Investors LLC with 20.3%.

Funds and institutions (13F) 90%Everyone else 10%

10 largest owners, by share of the company

Bain Capital Investors LLC20.3%
Bain Capital Life Sciences Investors, LLC17.4%
Rtw Investments, LP8.3%
Canada Pension Plan Investment Board5.6%
Atlas Venture Life Science Advisors, LLC4.0%
FMR LLC (Fidelity)3.1%
BlackRock, Inc.3.0%
T. Rowe Price Associates2.7%
Citadel Advisors LLC2.5%
Adage Capital Partners Gp, L.l.c.2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bain Capital Investors LLC26.26M20.25%$578M–
Bain Capital Life Sciences Investors, LLC22.58M17.42%$498M–
Rtw Investments, LP10.78M8.31%$237M–
Canada Pension Plan Investment Board7.30M5.63%$161M–
Atlas Venture Life Science Advisors, LLC5.17M3.99%$114M–
FMR LLC (Fidelity)3.97M3.06%$87.5M–
BlackRock, Inc.3.93M3.03%$86.5M–
T. Rowe Price Associates3.53M2.73%$77.9M–
Citadel Advisors LLC3.24M2.50%$71.4M–
Adage Capital Partners Gp, L.l.c.3.21M2.47%$70.7M–
Wellington Management Group LLP2.92M2.25%$64.3M–
Royalty Pharma Sub-Manager, LLC2.46M1.89%$54.1M–
Siren, L.L.C.2.21M1.71%$48.8M–
Vanguard Capital Management LLC1.69M1.31%$37.3M–
Vanguard Portfolio Management LLC1.65M1.27%$36.4M–
Geode Capital Management, LLC1.13M0.87%$25M–
Frazier Life Sciences Management, L.P.1.10M0.85%$24.2M–
Farallon Capital Management, L.l.c.1.10M0.85%$24.2M–
Trails Edge Capital Partners, LP984,7860.76%$21.7M–
UBS Group AG972,6830.75%$21.4M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KLRA insiders reported $167M of open-market purchases and $0 of sales.

Purchases, 12 months
$167M
3 trades, 3 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Apr 20, 2026
Filed Apr 22, 2026

Purchases and sales by month

$167M$167MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 20, 2026Rtw Investments, Lp +110% ownerPurchase500,000$16.00$8MForm 4
Apr 20, 2026BCPE Perseus Investor, LP +410% ownerPurchase8.40M$16.00$134MForm 4
Apr 20, 2026Adam KoppelDirectorPurchase1.56M$16.00$25MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
BCPE Perseus Investor, LP10% owner$134M–Apr 20, 2026
Adam KoppelDirector, 10% owner$25M–Apr 20, 2026
Rtw Investments, Lp10% owner$8M–Apr 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KLRA short interest

Moderate short interest. 6.3% of KLRA shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 207%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.16M KLRA shares were sold short, 6.3% of the shares outstanding, down 1.8% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

6.29%Aug 14Oct 307.05%

Days to cover

7.8May 15Oct 3022.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.16M6.29%-2%1.04M7.8
Oct 15, 20268.32M6.41%-4%1.46M5.7
Sep 30, 20268.68M6.70%+46%1.55M5.6
Sep 15, 20265.96M4.60%+5%782,1147.6
Aug 31, 20265.66M4.37%-7%876,6896.5
Aug 14, 20266.07M4.68%-8%302,11720.1
Jul 31, 20266.63M–+3%501,01313.2
Jul 15, 20266.41M–+26%692,9049.3
Jun 30, 20265.10M–+96%1.67M3.1
Jun 15, 20262.60M–-3%447,2485.8
May 29, 20262.69M–+1%418,0656.4
May 15, 20262.66M–+36%447,2955.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kailera Therapeutics company events

Kailera Therapeutics filed 4 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. May 26, 2026ResultsReleased financial results. Filing
  4. Apr 20, 2026AnnouncementThe Company completed its IPO of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at a public offering price of $16.00 per share. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold KLRA

5 of the 50 well-known investors we track reported holding KLRA in their latest 13F filing. The largest position is Ken Griffin's, worth $41.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20263.65M$41.7M0.0%+13%
Israel Englander · Millennium ManagementQ3 2026858,972$9.8M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 2026230,115$2.6M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026198,549$2.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202695,487$1.1M0.0%+99%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Kailera Therapeutics, Inc. (KLRA) stock

Who owns the most KLRA stock?

The largest reported owner of Kailera Therapeutics, Inc. (KLRA) is Bain Capital Investors LLC, with 20.3% of the company. In total, 100 funds and institutions reported holding KLRA at the end of Q2 2026, together about 90% of the shares. See the largest owners.

Are KLRA insiders buying or selling?

In the last 12 months, KLRA insiders reported 3 open-market purchases worth $167M and no sales. The latest trade was on Apr 20, 2026. See every trade.

What is the short interest in KLRA?

As of Oct 30, 2026, 8.16M KLRA shares were sold short, 6.3% of the shares outstanding, down 1.8% from the report before. At the average daily volume of 1.04M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold KLRA?

5 of the 50 well-known investors we track reported KLRA in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $41.7M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.